Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AB821 |
| Synonyms | |
| Therapy Description |
AB821 is a fusion protein comprising a mutated form of IL-21 fused to an antibody targeting CD8, which potentially increases T-cell-mediated antitumor immune activity (Journal for ImmunoTherapy of Cancer 2023;11, Suppl_1). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AB821 | AB-821|AB 821 | AB821 is a fusion protein comprising a mutated form of IL-21 fused to an antibody targeting CD8, which potentially increases T-cell-mediated antitumor immune activity (Journal for ImmunoTherapy of Cancer 2023;11, Suppl_1). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07027488 | Phase I | AB821 | AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors (Asher-BioAB821) | Recruiting | USA | 0 |